14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IONX vs ACB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONX carries a Unified Composite Score of 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin), whereas ACB carries 40.1/100 (SELL) at $4.61 (109.9x Forward P/E, -13.8% operating margin).
Composite vs. Pillar Nuance: While IONX currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. ACB 40.1/100 SELL), ACB captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. N/A operating margin) and revenue trajectory (-8.8% vs. N/A YoY).
Technical & Structure Timing Caution: IONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile ACB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IONX vs ACB. Trailing 12-month operating profitability (IONX N/A vs ACB -13.8%) and valuation multiples (IONX N/M vs ACB 109.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $324.8M market capitalization and -13.8% operating margin.
OpEx & R&D Reinvestment58.0% of Rev ($182M)
90D Engineering Disclosures0 Published
Investor FAQ IONX vs ACB Key Questions & Quantitative Answers
As of Nov 16, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONX carries a Unified Composite Score of 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin), whereas ACB carries 40.1/100 (SELL) at $4.61 (109.9x Forward P/E, -13.8% operating margin). Composite vs. Pillar Nuance: While IONX currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. ACB 40.1/100 SELL), ACB captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. N/A operating margin) and revenue trajectory (-8.8% vs. N/A YoY). Technical & Structure Timing Caution: IONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile ACB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACB leads the Growth & Scale pillar: IONX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACB at -8.8% YoY revenue growth and -94.7% YoY earnings growth on $314M TTM revenue (44.2% gross margin, -13.8% operating margin). On trailing 12-month operating scale, IONX generates N/A in USD-normalized revenue versus $314M for ACB. In operating R&D and SG&A reinvestment, IONX deploys N/A (0 90-day corporate R&D disclosures) versus 58.0% of Rev ($182M) (0 disclosures) for ACB.
ACB screens cheaper on headline valuation multiples. IONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACB trades at 109.9x Forward P/E, 109.9x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONX (N/A ROE) versus ACB (-9.4% ROE) capital efficiency.
In options market volatility and institutional positioning, IONX carries 181.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.79β · 232% Vol realized risk). By comparison, ACB carries 30.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.